GO with the first
FDA‑approved β3-
adrenergic agonist1

See how Myrbetriq® (mirabegron extended-release tablets) targets the β3‑AR pathway

Myrbetriq is not an antimuscarinic agent.1 It targets a different receptor signaling pathway—the β3-adrenergic receptor (AR) pathway.

Overactive bladder (OAB) is characterized by involuntary contraction of the detrusor
muscle during the storage phase.2

  • Myrbetriq relaxes the detrusor smooth muscle during the storage phase of the
    urinary bladder fill-void cycle by activation of the β3-AR1

    • As a result, bladder capacity is increased

  • Mirabegron is an agonist of the human β3-AR as demonstrated by in vitro
    laboratory experiments using the cloned human β3-AR1

  • Although mirabegron showed very low intrinsic activity for cloned human β1-AR and
    β2- AR, results in humans indicate that β1-AR stimulation occurred at a dose of 200 mg1

According to the AUA/SUFU Guideline, behavioral
therapies may be combined with Myrbetriq as a
first-line treatment option3

Other pharmacologic treatment options may also be combined with behavioral therapies
for first-line use. Adapted from AUA/SUFU (American Urological Association/Society of
Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction) non-neurogenic
OAB guidelines.

Dr. Nathaniel Barnes explains how Myrbetriq works

Watch this video about the first FDA‑approved β3‑adrenergic agonist. See how Myrbetriq
targets the β3‑AR pathway.

Important Safety Information,
Indications and Usage

Show more Show less


MYRBETRIQ® (mirabegron extended-release tablets), either alone or in combination with the muscarinic antagonist solifenacin succinate, is indicated for the treatment of overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency.


MYRBETRIQ is contraindicated in patients with known hypersensitivity reactions to mirabegron or any inactive ingredients of the tablet.

MYRBETRIQ monotherapy or in combination with solifenacin succinate can increase blood pressure in adults. Periodic blood pressure determinations are recommended, especially in hypertensive patients. MYRBETRIQ is not recommended for use in patients with severe uncontrolled hypertension (defined as systolic blood pressure ≥ 180mm Hg and/or diastolic blood pressure ≥ 110mm Hg). Worsening of pre-existing hypertension was reported infrequently in patients taking MYRBETRIQ.

In patients taking MYRBETRIQ, urinary retention has been reported in patients with bladder outlet obstruction (BOO) and in patients taking muscarinic antagonist medications for the treatment of OAB. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in patients treated with mirabegron; however, MYRBETRIQ should still be administered with caution to patients with clinically significant BOO. For example, monitor these patients for signs and symptoms of urinary retention. MYRBETRIQ should also be administered with caution to patients taking muscarinic antagonist medications for the treatment of OAB, including solifenacin succinate.

Angioedema of the face, lips, tongue and/or larynx has been reported with MYRBETRIQ. In some cases, angioedema occurred after the first dose. Cases have been reported to occur hours after the first dose or after multiple doses. Angioedema, associated with upper airway swelling, may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, promptly discontinue MYRBETRIQ and initiate appropriate therapy and/or measures necessary to ensure a patent airway.

Since MYRBETRIQ is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6 substrates is increased when co‐administered with MYRBETRIQ. Therefore, appropriate monitoring and dose adjustment may be necessary, especially with narrow therapeutic index drugs metabolized by CYP2D6.

In clinical trials, the most commonly reported adverse reactions in adults (> 2% and > placebo) for MYRBETRIQ 25mg and 50mg versus placebo, respectively, were hypertension (11.3%, 7.5% vs. 7.6%), nasopharyngitis (3.5%, 3.9% vs. 2.5%), urinary tract infection (4.2%, 2.9% vs. 1.8%), and headache (2.1%, 3.2% vs. 3.0%).

In clinical trials, the most commonly reported adverse reactions in adults (> 2% and > placebo and > comparator) for MYRBETRIQ in combination with solifenacin succinate 25mg + 5mg and 50mg + 5mg versus MYRBETRIQ 25mg, MYRBETRIQ 50mg, solifenacin succinate 5mg, and placebo, respectively, were dry mouth (9.3%, 7.2% vs. 3.8%, 3.6%, 6.5%, 2.2%), urinary tract infection (7.0%, 4.0% vs. 4.0%, 4.2%, 3.6%, 5.3%), constipation (4.2%, 3.9% vs. 1.2%, 2.8%, 2.4%, 1.2%), and tachycardia (2.2%, 0.9% vs. 1.6%, 1.6%, 0.7%, 0.8%).

In postmarketing experience with mirabegron, the following events have also occurred: atrial fibrillation, nausea, diarrhea, and dizziness.

Please refer to prescribing information for solifenacin succinate when prescribing MYRBETRIQ in combination with solifenacin succinate.

Please click here for complete Prescribing Information for MYRBETRIQ® (mirabegron extended-release tablets)


1. Myrbetriq [package insert]. Northbrook, IL: Astellas Pharma US, Inc. 2. Chu FM, Dmochowski R. Pathophysiology of overactive bladder. Am J Med. 2006;119(3 Suppl 1):3S‑8S. 3. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association Education and Research, Inc. 2019.